PMID- 30235496
OWN - NLM
STAT- MEDLINE
DCOM- 20191219
LR  - 20191219
IS  - 1439-0795 (Electronic)
IS  - 0176-3679 (Linking)
VI  - 52
IP  - 4
DP  - 2019 Jul
TI  - Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse 
      Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled 
      Study.
PG  - 180-185
LID - 10.1055/a-0669-9461 [doi]
AB  - INTRODUCTION: The aim of this double-blind randomized study was to evaluate the 
      response to antipsychotic treatment in schizophrenia patients with predicted 
      high/low risk of nonresponse identified by applying a set of well-established 
      scales and predictors of outcome and to compare efficacy between ziprasidone and 
      haloperidol. METHODS: One hundred twelve schizophrenia patients (ziprasidone: 
      n=54; haloperidol: n=58) were rated weekly on the Positive and Negative Syndrome 
      Scale for Schizophrenia (PANSS), the Global Assessment of Functioning Scale 
      (GAF), the Social and Occupational Functioning Scale (SOFAS), the Simpson-Angus 
      Scale (SAS), and Hillside Akathisia Scale (HAS). RESULTS: Ninety-two patients 
      (82%) were predicted to have a high risk of nonresponse. No significant 
      difference regarding PANSS improvement in this subsample was found comparing 
      ziprasidone and haloperidol (p=0.563). Also, for the total patient sample, no 
      significant difference was found regarding the course of the PANSS total score, 
      GAF (p=0.921), and SOFAS (p=0.658) between ziprasidone and haloperidol. 
      Haloperidol resulted in higher scores on the SAS (p=0.001) and HAS (p=0.011). 
      DISCUSSION: An alarmingly high number of patients were at high risk of 
      nonresponse to antipsychotic treatment.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Schennach, Rebecca
AU  - Schennach R
AD  - Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
AD  - Schoen Clinic Roseneck, Prien am Chiemsee, Germany.
FAU - Riedel, Michael
AU  - Riedel M
AD  - Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
AD  - Psychiatric Clinic Rodewisch, Rodewisch, Germany.
FAU - Spellmann, Ilja
AU  - Spellmann I
AD  - Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
AD  - Psychiatric Clinic, Stuttgart, Germany.
FAU - Musil, Richard
AU  - Musil R
AD  - Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
FAU - Obermeier, Michael
AU  - Obermeier M
AD  - Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
FAU - Jager, Markus
AU  - Jager M
AD  - Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
AD  - Psychiatric Clinic, District Hospital Kempten, Kempten, Germany.
FAU - Bottlender, Roland
AU  - Bottlender R
AD  - Psychiatric Clinic, District Hospital Ludenscheid, Ludenscheid, Germany.
FAU - Schmauss, Max
AU  - Schmauss M
AD  - Psychiatric Clinic, District Hospital Augsburg, Augsburg, Germany.
FAU - Laux, Gerd
AU  - Laux G
AD  - Psychiatric Clinic, Inn-Salzach Hospital Wasserburg/Inn, Wasserburg, Germany.
FAU - Moller, Hans-Jurgen
AU  - Moller HJ
AD  - Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20180920
PL  - Germany
TA  - Pharmacopsychiatry
JT  - Pharmacopsychiatry
JID - 8402938
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Thiazoles)
RN  - 6UKA5VEJ6X (ziprasidone)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
EIN - Pharmacopsychiatry. 2019 Jul;52(4):e1. PMID: 32102096
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Haloperidol/*therapeutic use
MH  - Humans
MH  - Interpersonal Relations
MH  - Male
MH  - Middle Aged
MH  - Piperazines/*therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Risk Assessment
MH  - Schizophrenia/*drug therapy
MH  - Severity of Illness Index
MH  - Thiazoles/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
COIS- The authors report no financial conflict of interests within the context of this 
      article.
EDAT- 2018/09/21 06:00
MHDA- 2019/12/20 06:00
CRDT- 2018/09/21 06:00
PHST- 2018/09/21 06:00 [pubmed]
PHST- 2019/12/20 06:00 [medline]
PHST- 2018/09/21 06:00 [entrez]
AID - 10.1055/a-0669-9461 [doi]
PST - ppublish
SO  - Pharmacopsychiatry. 2019 Jul;52(4):180-185. doi: 10.1055/a-0669-9461. Epub 2018 
      Sep 20.